GlassScriptPhysician profile
Dhiraj Narula
NPI 1558399485
$13,721.45
in general payments reported to CMS, 2019-2025
42 companies · $3,057 in 2025
The $3,057 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,519 · 2020: $628 · 2021: $1,279 · 2022: $1,944 · 2023: $1,546 · 2024: $3,749 · 2025: $3,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,387 · Travel and Lodging: $2,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,387.09 |
| Travel and Lodging | $2,964.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,904.07 | 2019-2025 | Farapulse, Watchman Flx, Watchman Access System |
| Medtronic, INC. | $2,503.96 | 2021-2025 | Pulseselect, Affera Mapping System, Micra |
| Abbott Laboratories | $2,167.97 | 2019-2025 | Aveir, Ensite, Cardiomems |
| Medtronic Vascular, INC. | $1,273.47 | 2019-2020 | |
| Atricure, INC. | $1,067.29 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $516.98 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $461.22 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $386.30 | 2021-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $320.55 | 2020-2023 | Xarelto |
| Biosense Webster, INC. | $306.40 | 2021-2025 | Qdot Micro Catheter, Nuvision Ice Catheter, Carto 3 |
| Roche Diagnostics Corporation | $208.90 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $205.80 | 2020-2024 | Lifevest |
| Cvrx, INC. | $163.29 | 2023-2025 | Barostim Neo System |
| Sunovion Pharmaceuticals INC. | $119.11 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $86.56 | 2024 | Arcalyst |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhiraj Narula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.